Kenneth Mark, MD
MOHS-Micrographic Surgery · Southampton, NYNPI 1538199310
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $80,275 of the $90,568 with a category attached, or 88.6%. AbbVie accounts for 89.1% of it on its own, with 2 other manufacturers making up the rest. Reporting peaked in 2023 at $27,721 and has fallen 52.6% since, to $13,140 in 2025. Among mohs-micrographic surgery clinicians in NY with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 103 payments — averaging $879.31 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$81K
- Genentech USA, Inc.$10K
- Merz North America, Inc.$131
What the payments were for
- Speaking & faculty fees$80,27589%
- Travel & lodging$7,6938%
- Food & beverage$2,6003%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 94 | $80,680 |
| Genentech USA, Inc. | 8 | $9,758 |
| Merz North America, Inc. | 1 | $131 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$90,568 in reported general payments places this provider in the 90th percentile of 75 mohs-micrographic surgery providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Clobetasol Propionate | 80 | $2,909 |
| ValacyclovirValacyclovir Hcl | 49 | $1,713 |
| Triamcinolone Acetonide | 127 | $925 |
| Doxycycline Hyclate | 52 | $840 |
| Mupirocin | 71 | $786 |
| Ketoconazole | 34 | $627 |
| Cefadroxil | 43 | $410 |
| Cephalexin | 21 | $206 |
| Clindamycin Hcl | 13 | $49 |
Paid to pharmacies, not to this prescriber.
Other mohs-micrographic surgery in Southampton
- Daniel SiegelSmithtown$450K
- Sherrif IbrahimVictor$412K
- Kavita MariwallaWest Islip$221K
- Ellen MarmurNew York$186K
- Michael TassavorNew York$55K
- Jane YooNew York$42K
- Hamza BhattiNew York$40K
- Desiree RatnerNew York$32K
- Eyal LevitBrooklyn$22K
- Omar Torres LozadaNew York$13K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.